BRPI0702640A - processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos - Google Patents

processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos

Info

Publication number
BRPI0702640A
BRPI0702640A BRPI0702640-4A BRPI0702640A BRPI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A
Authority
BR
Brazil
Prior art keywords
application
receptor sites
flavonoid
benzodiazepine receptor
brain
Prior art date
Application number
BRPI0702640-4A
Other languages
English (en)
Inventor
Sibila Roberta Marqu Grallertr
Leoberto Costa Tavares
Elaine Bortoleti De Araujo
Original Assignee
Comissao Nac Energia Nuclear
Univ Sao Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comissao Nac Energia Nuclear, Univ Sao Paulo filed Critical Comissao Nac Energia Nuclear
Priority to BRPI0702640-4A priority Critical patent/BRPI0702640A/pt
Priority to PCT/BR2008/000005 priority patent/WO2008083454A1/en
Publication of BRPI0702640A publication Critical patent/BRPI0702640A/pt

Links

Classifications

    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
    • G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for 
    • G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for  as tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Abstract

PROCESSO DE RADIOMARCAçãO DE FLAVONóIDES E SUA APLICAçãO EM DIAGNóSTICO IN VIVO DE DISFUNçõES CEREBRAIS RELACIONADAS AOS SìTIOS RECEPTORES BENZODIAZEPìNICOS. Compreende um estudo referente ao desenvolvimento radioquímico de flavonóides radiomarcados e aplicação in vivo como agentes de imageamento cerebral frente a sítios receptores benzodiazepínicos, utilizando-se técnicas tomográficas, em dito processo foi estudada a marcação de flavonóides via substituição eletrofilica aromática e biodistribuição de flavona radiomarcada em camungongos Swiss. Os resultados indicam elevada concentração do radiotraçador no cérebro, principalmente até 30 minutos após a injeção do radiocomposto, compatíveis com a utilização clínica como agente de imageamento e com grande potencial para aplicação em medicina nuclear diagnóstica.
BRPI0702640-4A 2007-01-10 2007-01-10 processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos BRPI0702640A (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0702640-4A BRPI0702640A (pt) 2007-01-10 2007-01-10 processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos
PCT/BR2008/000005 WO2008083454A1 (en) 2007-01-10 2008-01-08 Process for flavonoids radiolabeling and its application on in vivo diagnosis of brain malfunctions related to benzodiazepine receiving sites

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0702640-4A BRPI0702640A (pt) 2007-01-10 2007-01-10 processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos

Publications (1)

Publication Number Publication Date
BRPI0702640A true BRPI0702640A (pt) 2008-08-26

Family

ID=39608273

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0702640-4A BRPI0702640A (pt) 2007-01-10 2007-01-10 processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos

Country Status (2)

Country Link
BR (1) BRPI0702640A (pt)
WO (1) WO2008083454A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046378A1 (en) * 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
KR20110046503A (ko) 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450149A (en) * 1981-06-15 1984-05-22 Research Corporation Radiohalogenation method

Also Published As

Publication number Publication date
WO2008083454A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
Kuntner et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11 C] verapamil PET
Ettrup et al. Radiosynthesis and in vivo evaluation of a series of substituted 11 C-phenethylamines as 5-HT 2A agonist PET tracers
Kuntner et al. Quantitative preclinical PET imaging: opportunities and challenges
Zimmer et al. PET radiotracers for molecular imaging in the brain: past, present and future
Bankstahl et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood–brain barrier studied with (R)-11C-verapamil and PET
Yamamoto et al. Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys
Collingridge et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope
Ory et al. PET radioligands for in vivo visualization of neuroinflammation
DeLorenzo et al. Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C] ABP688
Zheng et al. [11C] Choline as a PET biomarker for assessment of prostate cancer tumor models
Herfert et al. Quantitative rodent brain receptor imaging
BRPI0702640A (pt) processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
Parent et al. PET imaging of cholinergic deficits in rats using [18F] fluoroethoxybenzovesamicol ([18F] FEOBV)
Elmenhorst et al. Test‐retest stability of cerebral mGluR5 quantification using [11C] ABP688 and positron emission tomography in rats
Shen et al. Radiosynthesis and first-in-human PET/MRI evaluation with clinical-grade [18 F] FTC-146
McCormick et al. Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release
Patel et al. Bimodal imaging of inflammation with SPECT/CT and MRI using iodine-125 labeled VCAM-1 targeting microparticle conjugates
Fan et al. 68Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human Glioblastoma
WO2009143101A3 (en) Gastrin releasing peptide compounds
Montemagno et al. In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor
Varrone et al. Simplified quantification and whole-body distribution of [18F] FE-PE2I in nonhuman primates: prediction for human studies
Murthy et al. Whole body [11 C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates
D'Elia et al. Role of nuclear imaging to understand the neural substrates of brain disorders in laboratory animals: current status and future prospects
Hwang et al. Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18 F] AMG 580 in non-human primates

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)
B08E Application fees: requirement for complementation of annuity fee

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 3A., 4A., 7A. ANUIDADE(S), DE ACORDO COM TABELA VIGENTE, REFERENTE A(S) GUIA(S) DE RECOLHIMENTO 0000220903513720, 0000221002127402 E 0000221303691510, RESPECTIVAMENTE E COMPROVAR O RECOLHIMENTO DA 9A. ANUIDADE E A TAXA DE RESTAURACAO DA 5A.

B08G Application fees: restoration
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements